Also listed on Bellicum Pharmaceuticals, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Jun 23, 2034 · Medium confidence
20-year base term ends Jun 4, 2034
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 10,525,110), so the cap could be lower.
Jun 4, 2014
Jun 23, 2034
Dec 12, 2023
This patent's term runs 900 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 0 of 2 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 4, 2014, when application 14/296,404, the earliest non-provisional in its chain, was filed (this one was filed Jan 3, 2020) | Jun 4, 2034 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +900 days, USPTO patent term adjustment record | Nov 20, 2036 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,525,110, US 9,913,882) | capped to Jun 23, 2034 | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 23, 2034 | Medium confidence |
This family
| US 9,434,935 | In force Mar 2033 | Mar 2033 |
| Application PCT/US2014/022004 | PCT application no patent term | no patent term |
| US 9,944,690 | In force Mar 2034 | Mar 2034 |
| US 9,913,882 | In force Feb 2035 | Feb 2035 |
| US 10,888,608 | In force Sep 2035 | Sep 2035 |
| Application 14/968,737 | Abandoned not computed | not computed |
| Application 14/968,853 | Abandoned not computed | not computed |
| US 9,932,572 | In force Mar 2033 | Mar 2033 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 1, 2020 Reel 52284, frame 113 | Bellicum Pharmaceuticals, Inc. | Oxford Finance LLC, as Collateral Agent | Security Interest |
| Aug 18, 2020 Reel 53531, frame 294 | Slawin, Kevin; Spencer, David; Foster, Aaron Edward | Bellicum Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Nov 3, 2020 Reel 54295, frame 946 | Oxford Finance LLC, as Collateral Agent | Bellicum Pharmaceuticals, Inc. | Release of Security Interest |
| Feb 21, 2024 Reel 66643, frame 549 | Bellicum Pharmaceuticals, Inc. | Board of Regents of the University of Texas System | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,525,110, US 9,913,882.